Literature DB >> 16521050

A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis.

Masahide Hamaguchi1, Yutaka Kawahito, Hidetaka Ishino, Makie Yoshida, Toshikazu Yoshikawa.   

Abstract

It is commonly believed that infliximab-induced anticardiolipin antibody belongs to the IgM subclass but not the IgG subclass and that the IgM subclass could not produce clinical symptoms. However, we had a patient with scleroderma overlap/rheumatoid arthritis who developed thrombocytopenia associated with the appearance of IgM anticardiolipin antibody after treatment with infliximab. This is a report of a rare case that should make us aware of the possibility of the development of thrombocytopenia with the appearance of IgM anticardiolipin antibody induced by infliximab.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16521050     DOI： 10.1007/s10067-006-0229-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   3.650


  9 in total

1.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

2.  Drug-induced systemic lupus erythematosus associated with etanercept therapy.

Authors:  Najia Shakoor; Margaret Michalska; Charlotte A Harris; Joel A Block
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

Review 3.  Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.

Authors:  Marc Feldmann; Ravinder N Maini
Journal:  Joint Bone Spine       Date:  2002-01       Impact factor: 4.929

4.  Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.

Authors:  Leen De Rycke; Dominique Baeten; Elli Kruithof; Filip Van den Bosch; Eric M Veys; Filip De Keyser
Journal:  Arthritis Rheum       Date:  2005-07

Review 5.  Does safety make a difference in selecting the right TNF antagonist?

Authors:  Roy Fleischmann; David Yocum
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

Review 6.  TNFalpha as therapeutic target: new drugs, more applications.

Authors:  A M Reimold
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2002-12

7.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

Review 8.  Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.

Authors:  Larry W Moreland
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.

Authors:  Carole Ferraro-Peyret; Fabienne Coury; Jacques G Tebib; Jacques Bienvenu; Nicole Fabien
Journal:  Arthritis Res Ther       Date:  2004-09-23       Impact factor: 5.156
  9 in total
  4 in total

1.  Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease.

Authors:  Antonio Salar; Xavier Bessa; Eduard Muñiz; David Monfort; Carlos Besses; Montserrat Andreu
Journal:  Gut       Date:  2007-03-07       Impact factor: 23.059

Review 2.  Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoes.

Authors:  Debbie A Gladd; Ewa Olech
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 3.  Hematologic side effects of biologics and kinase inhibitors used in rheumatologic diseases: a review of the current evidence.

Authors:  Sambhawana Bhandari; Maun Ranjan Baral; Matthew Barbery; Alla Rudinskaya; Oleg Sostin
Journal:  Ann Hematol       Date:  2022-06-27       Impact factor: 4.030

4.  Current Perspectives on the Role of TNF in Hematopoiesis Using Mice With Humanization of TNF/LT System.

Authors:  Violetta S Gogoleva; Kamar-Sulu N Atretkhany; Arina P Dygay; Taisiya R Yurakova; Marina S Drutskaya; Sergei A Nedospasov
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.